Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Zeev's Turnips - No Politics -- Ignore unavailable to you. Want to Upgrade?

To: shoreco who wrote (75792)	6/7/2002 7:22:24 AM
From: Jay k.	Read Replies (1) \| Respond to of 99280

Warning from BGEN also. CAMBRIDGE, Mass., June 7 /PRNewswire-FirstCall/ -- Biogen, Inc. (Nasdaq: BGEN - News) today announced revised financial guidance for the second quarter and full year 2002, due to inventory adjustments by AVONEX U.S. wholesalers in both April and May and softer than expected overall U.S. market growth. "We carefully reviewed market growth, distribution channel inventories and AVONEX demand to understand the sales shortfall," said James C. Mullen, Biogen's President and CEO. "The overall market growth in the U.S. is five percent below our forecast. Our market share according to IMS data changed from 57.4 percent in December to 56.9 percent in April. Wholesalers have reduced inventory levels from about 15 days to 10 days, which represents $11 million of sales. Our revised guidance assumes this new inventory will not change over the balance of the year." U.S. MS Market Growth Softer than Expected biz.yahoo.com